Overexpression of c-erbB-2 protein in gastric cancer. Its correlation with long-term survival of patients

Cancer. 1993 Dec 1;72(11):3179-84. doi: 10.1002/1097-0142(19931201)72:11<3179::aid-cncr2820721108>3.0.co;2-#.

Abstract

Background: Overexpression of c-erbB-2 protein in breast cancer has been reported to be associated with poor prognosis. However, clinical significance of c-erbB-2 protein overexpression has not been demonstrated clearly in gastric cancer.

Methods: Immunohistochemical reactivity to c-erbB-2 protein was examined in formalin-fixed, paraffin-embedded tissue sections from patients with gastric cancer.

Results: First, primary stomach cancers in 106 patients were examined. Among 58 cases of papillary or well- to moderately differentiated tubular adenocarcinoma, staining of c-erbB-2 protein was positive on the plasma membrane of cancer cells in 8 cases (14%). Conversely, among 47 cases of poorly differentiated adenocarcinoma or signet ring cell carcinoma, positive staining of c-erbB-2 protein was detected in one case only (2%), where the histopathologic type was poorly differentiated adenocarcinoma with a cohesive structure. Among tubular adenocarcinomas, no significant association was shown between overexpression of c-erbB-2 protein and the depth of tumor invasion, extent of lymph node metastasis, or tumor location. To investigate the correlation between the staining of c-erbB-2 protein and prognosis in gastric cancer, an additional 108 cases of papillary or well- to moderately differentiated tubular adenocarcinoma invasive as far as the muscularis propria were examined immunohistochemically for expression of c-erbB-2 protein. Twelve cases (11%) showed positive staining on the plasma membrane, and their survival curve showed a significantly poorer prognosis (P < 0.01).

Conclusions: These results suggest that overexpression of c-erbB-2 protein occurs selectively in cohesive gastric cancer, and it can be considered an important prognostic indicator.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / genetics
  • Adenocarcinoma / metabolism
  • Adenocarcinoma / pathology
  • Adenocarcinoma / secondary
  • Adenocarcinoma, Papillary / genetics
  • Adenocarcinoma, Papillary / metabolism
  • Adenocarcinoma, Papillary / pathology
  • Adenocarcinoma, Papillary / secondary
  • Biomarkers, Tumor / analysis
  • Biomarkers, Tumor / biosynthesis
  • Biomarkers, Tumor / genetics*
  • Carcinoma, Signet Ring Cell / genetics
  • Carcinoma, Signet Ring Cell / metabolism
  • Carcinoma, Signet Ring Cell / pathology
  • Cell Membrane / metabolism
  • Cell Membrane / ultrastructure
  • ErbB Receptors / analysis
  • ErbB Receptors / biosynthesis
  • ErbB Receptors / genetics*
  • Follow-Up Studies
  • Gastric Mucosa / metabolism
  • Gastric Mucosa / pathology
  • Gene Expression Regulation, Neoplastic*
  • Humans
  • Lymphatic Metastasis / pathology
  • Neoplasm Invasiveness
  • Neoplasm Recurrence, Local
  • Prognosis
  • Proto-Oncogene Proteins / analysis
  • Proto-Oncogene Proteins / biosynthesis
  • Proto-Oncogene Proteins / genetics*
  • Receptor, ErbB-2
  • Stomach Neoplasms / genetics
  • Stomach Neoplasms / metabolism*
  • Stomach Neoplasms / pathology
  • Survival Rate

Substances

  • Biomarkers, Tumor
  • Proto-Oncogene Proteins
  • ErbB Receptors
  • Receptor, ErbB-2